<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922607</url>
  </required_header>
  <id_info>
    <org_study_id>M17-238</org_study_id>
    <nct_id>NCT03922607</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in&#xD;
      healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the&#xD;
      efficacy of ABBV-157 in the participants with psoriasis. This study consists of two&#xD;
      substudies. Substudy 1 is a randomized, double-blind, placebo-controlled evaluation of&#xD;
      multiple ascending oral doses of ABBV-157 in healthy adult volunteers. Substudy 2 is a&#xD;
      randomized, double-blind, placebo-controlled study in which participants with moderate to&#xD;
      severe chronic plaque psoriasis will be administered multiple oral doses of ABBV-157.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Actual">April 13, 2021</completion_date>
  <primary_completion_date type="Actual">April 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substudy 1: Cmax of ABBV-157</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Tmax of ABBV-157</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>Time to maximum observed plasma concentration (Tmax) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: AUC0-24 Post-dose of ABBV-157</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of ABBV-157.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Trough Concentration (Ctrough) of ABBV-157</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: AUCtau of ABBV-157</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>The area under the plasma concentration-time curve over a dosing interval of tau (AUCtau).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Clearance is defined as the volume of plasma cleared of the drug per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Volume of Distribution (Vβ/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Volume of Distribution (Vβ/F) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Apparent Terminal Phase Elimination Constant (β)</measure>
    <time_frame>Day 14</time_frame>
    <description>Apparent Terminal phase elimination rate constant (β or Beta)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Elimination Half-Life (t1/2)</measure>
    <time_frame>Day 14</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Fraction Excreted Unchanged in Urine (fe)</measure>
    <time_frame>Day 14</time_frame>
    <description>Fraction excreted unchanged in urine (fe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Apparent Renal Clearance (CLR)</measure>
    <time_frame>Day 14</time_frame>
    <description>Apparent Renal Clearance (CLR) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Accumulation ratio for Cmax</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>Accumulation ratio for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1: Accumulation Ratio for AUCtau</measure>
    <time_frame>Up to approximately 14 days</time_frame>
    <description>Accumulation Ratio for AUCtau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Cmax of ABBV-157</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Tmax of ABBV-157</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Time to maximum observed plasma concentration (Tmax) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: AUC0-24 Post-dose of ABBV-157</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of ABBV-157.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: AUCtau of ABBV-157</measure>
    <time_frame>Day 28</time_frame>
    <description>The area under the plasma concentration-time curve over a dosing interval of tau (AUCtau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Day 28</time_frame>
    <description>Clearance is defined as the volume of plasma cleared of the drug per unit time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Volume of Distribution (Vβ/F)</measure>
    <time_frame>Day 28</time_frame>
    <description>Volume of Distribution (Vβ/F) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Apparent Terminal Phase Elimination Constant (β)</measure>
    <time_frame>Day 28</time_frame>
    <description>Apparent Terminal phase elimination rate constant (β or Beta)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Elimination Half-Life (t1/2)</measure>
    <time_frame>Day 28</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Accumulation ratio for Cmax</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Accumulation ratio for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Accumulation Ratio for AUCtau</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Accumulation Ratio for AUCtau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Trough Concentration (Ctrough) of ABBV-157</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-157</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Percent Change in Psoriasis Area and Severity Index (PASI) score from Baseline</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) score quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Change in Self-Assessment of Psoriasis Symptoms (SAPS) Score from Baseline</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>SAPS is a self-assessment questionnaire of psoriasis symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to Day 58</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Substudy 2: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-157</intervention_name>
    <description>ABBV-157 will be administered orally as capsule</description>
    <arm_group_label>Substudy 1: Group 1</arm_group_label>
    <arm_group_label>Substudy 1: Group 2</arm_group_label>
    <arm_group_label>Substudy 1: Group 3</arm_group_label>
    <arm_group_label>Substudy 2: Group 1</arm_group_label>
    <arm_group_label>Substudy 2: Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-157</intervention_name>
    <description>Placebo for ABBV-157 will be administered orally as capsule</description>
    <arm_group_label>Substudy 1: Group 1</arm_group_label>
    <arm_group_label>Substudy 1: Group 2</arm_group_label>
    <arm_group_label>Substudy 1: Group 3</arm_group_label>
    <arm_group_label>Substudy 2: Group 1</arm_group_label>
    <arm_group_label>Substudy 2: Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteer should be between 18 and 55 years of age and in general good health for&#xD;
             Substudy 1 and participant with moderate to severe chronic plaque psoriasis between 18&#xD;
             and 75 years of age for Substudy 2 at the time of enrollment.&#xD;
&#xD;
          -  Participant should meet the laboratory assessments as mentioned in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a history of epilepsy, any significant cardiac, respiratory, renal,&#xD;
             hepatic, gastrointestinal, opthalmologic, hematologic,or psychiatric disease or&#xD;
             disorder, or any uncontrolled medical illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin and Beauty Derm Ctr /ID# 222593</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Dermatology and MOHs /ID# 222622</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials LLC /ID# 213645</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801-2658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Res. Assoc., CA /ID# 224980</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research /ID# 213339</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research /ID# 216090</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328-6141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acpru /Id# 213639</name>
      <address>
        <city>Grayslake</city>
        <state>Illinois</state>
        <zip>60030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 224699</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD PH I Clinical Unit /ID# 213062</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Webster TX /ID# 217352</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Chronic Plaque Psoriasis</keyword>
  <keyword>ABBV-157</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

